Mahlich, J., Groß, M., Kuhlmann, A., Bogner, J., Heiken, H., & Stoll, M. (2016). The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany. J Pharm Policy Pract.

Mahlich, Jörg, Mona Groß, Alexander Kuhlmann, Johannes Bogner, Hans Heiken, and Matthias Stoll. "The Choice between a Ritonavir-boosted Protease Inhibitor- and a Non-nucleoside Reverse Transcriptase Inhibitor-based Regimen for Initiation of Antiretroviral Treatment – Results From an Observational Study in Germany." J Pharm Policy Pract 2016.

Mahlich, Jörg, et al. "The Choice between a Ritonavir-boosted Protease Inhibitor- and a Non-nucleoside Reverse Transcriptase Inhibitor-based Regimen for Initiation of Antiretroviral Treatment – Results From an Observational Study in Germany." J Pharm Policy Pract 2016.